

Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients

Konstantinos Lemonakis,¹ Love Tättning,² Mikael Lisak,³ Kristina Carlson,⁴ Jacob Crafoord,⁵ Cecilie H Blimark,³ Antonio I. Santamaria,⁶ Stina Wichert,¹ Stig Lenhoff¹ and Markus Hansson³

¹Department of Hematology, Skåne University Hospital, Lund; ²Department of Hematology, University Hospital Linköping, Linköping; ³Department of Hematology, Sahlgrenska University Hospital, Gothenburg; ⁴Department of Hematology, University Hospital Uppsala, Uppsala; ⁵Department of Hematology, Örebro University Hospital, Örebro and ⁶Department of Hematology, Norrlands University Hospital, Umeå, Sweden

Correspondence: K. LEMONAKIS - Konstantinos.lemonakis@skane.se

<https://doi.org/10.3324/haematol.2022.281610>

Supplementary tables for manuscript titled “**Impact of daratumumab based induction on stem cell collection parameters in Swedish myeloma patients**”

Table S1. Baseline characteristics

	Daratumumab treated (n=92)	Non- Daratumumab treated (n=125)	p.
Median age (range)	61 (30-72)	63 (46-74)	0.303
Age>60	50 (54%)	80 (64%)	0.152
Gender			
Female	34 (37%)	47 (38%)	0.923
Bone disease	76/88 (86%)	100/123 (80%)	0.355
Anemia	24/73 (33%)	25/102 (24%)	0.277
Hypercalcemia	15/74 (20%)	10/99 (10%)	0.080
Renal failure	16/76 (21%)	10/102 (10%)	0.052
ISS			
I	24/77 (31%)	30/96 (31%)	
II	29/77 (38%)	46/96 (48%)	0.386
III	24/77 (31%)	20/96 (21%)	
High-risk cytogenetics	24/85 (28%)	37/105 (35%)	0.304
R-ISS			
I	10/64 (16%)	14/84 (17%)	
II	46/64 (72%)	58/84 (69%)	0.939
III	8/64 (12%)	12/84 (14%)	
BM plasma cells (%)	29%	30%	0.735

Table S2. Induction and mobilization parameters

	Daratumumab treated (n = 92)	Non- daratumumab treated (n=125)	p.
Induction parameters			
Lenalidomide	34 (37%)	107 (86%)	<0.001
Thalidomide	53 (58%)	12 (10%)	<0.001
Alkylators	4 (4%)	15 (12%)	0.055
radiation	13(14%)	20(16%)	0.849
Cyclophosphamide in mobilization	81 (88%)	121 (97%)	0.015
Induction cycles			
Median (range)	4 (3-6)	4 (3-10)	0.157
≤4	87 (95%)	109 (87%)	0.102
Response after induction			
≥VGPR	78 (86%)	79 (66%)	0.001
CR	19 (21%)	18 (15%)	0.279
VGPR	59 (65%)	61 (51%)	0.05
PR	13 (14%)	39 (33%)	0.002